REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products
17 March 2021
YOKOHAMA, March 16, 2021/ We are pleased to announce that our cell processing facility, REPROCELL Regenerative Medicine Center (located in Life Innovation Center in the Kanagawa region), was certified as manufacturing facility for cell cult...
Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease
15 March 2021
NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research organization (CRO), providing a unique co...
Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India
11 March 2021
Hyderabad India – 11 March 2021: Bioserve Biotechnologies Pvt Ltd, 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of Non-Invasive Prenatal Testing (NIPT) services in India.Under PRENITA brand, along with NIPT serv...
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
01 March 2021
[Glasgow, UK] REPROCELL has contributed to a novel publication detailing advancements in induced pluripotent stem cell (iPSC) reprogramming. The paper, published in New Biotechnology by Dr Amer Rana and his team of researchers from the Univ...
REPROCELL launches PCR Testing Service for COVID-19
01 March 2021
[Yokohama, Japan] REPROCELL will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc: a Japanese start-up company based on cutting-edge technologies developed by RIKEN, Japan’s largest comprehensi...
REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
25 February 2021
All patients have been registered at ten sites in Japan for the Phase II clinical trial of Stemchymal®, a human adipose-derived stem cell product exclusively licensed in Japan by Steminent Biotherapeutics Inc. (hereinafter referred to as St...
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
16 February 2021
[Hyderabad, India] Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced Bioserve Biotechnologies Pvt Ltd (REPROCELL’s 100% owned subsidiary) as the new distributor of its Maestro systems a...
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
17 December 2020
17 December 2020 [Japan, Yokohama]: REPROCELL has announced that they will launch a new service to generate individual specific induced pluripotent stem cell (iPSC) in January, “Personal iPS” service. REPROCELL will start taking orders from...
REPROCELL Becomes VIP Supplier on Scientist.com Biotech Marketplace
10 December 2020
Beltsville, USA: REPROCELL, an industry leader in the use of human biospecimens for medical research, has partnered with Scientist.com, the healthcare industry’s leading marketplace for life science research, to bring its services to the gl...
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
17 August 2020
Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projec...